Serum Institute of India 's Chief Executive Officer Adar Poonawalla has said their Covovax vaccine will get approval as a booster against COVID-19 in the next 10 to 15 days. The vaccine works very ...

NEW DELHI: The National Technical Advisory Group on Immunization (NTAGI) has approved the Serum Institute’s Covid-19 Covovax for the 12-17 age group. But, no decision has been taken on ...

Children aged 12 to 17 years can now get the Serum Institute’s coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for the Novavax and Serum Institute of India (SII) Covid-19 vaccine, Covovax, in the 12-18 age group.

A Covid working group of NTAGI will review this week data of Serum Institute of India's (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination ...

Coronavirus vaccine Covovax is now available for children in India, Serum Institute of India's CEO Adar Poonawalla said on May 3. Covovax is the only vaccine manufactured in India that is also ...

India's drug regulator in July had granted permission to Serum Institute of India (SII) for conducting a phase 2/3 trial of Covovax on children aged 2 to 17 years with certain conditions on the ...

NEW DELHI: India’s apex drug regulator has turned down a proposal by Serum Institute of India to test the Covid-19 vaccine Covovax on children, saying it needs to evaluate safety and ...

New Delhi: The subject expert committee on COVID-19 of India's drug regulator will on Friday review the applications of Serum Institute of India seeking emergency use authorisation to use Covovax ...

New Delhi: The Drugs Controller General of India (DCGI) granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults ...